On the evening of October 26, Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. (referred to as “Jinbo Bio”) released its financial report for the third quarter of 2023.
In the first three quarters of this year, the company achieved operating revenue of 517 million yuan, a year-on-year increase of 105.64%. The net profit attributable to shareholders of the listed company was 192 million yuan ($26.24 million), a year-on-year increase of 173.75%.
Specifically, in the third quarter of this year, the company achieved operating revenue of 201 million yuan ($27.47 million), a year-on-year increase of 106.43%. The net profit attributable to shareholders of the listed company was 82.8427 million yuan ($11.32 million), a year-on-year increase of 168.75%. The company stated that the growth in performance was mainly due to an increase in sales scale and revenue.
In August, the National Medical Products Administration approved the registration application for the innovative product, an injection of recombinant Type III human collagen solution, produced by Jinbo Biomedical. It is reported that the product utilizes recombinant collagen biological material that can be assembled into a collagen fiber network, providing support to cells and tissues. It physically fills the areas where wrinkles and sagging occur, suitable for dermal tissue filling in the face to correct dynamic wrinkles in the forehead area (including frown lines, forehead wrinkles, and crow’s feet).